MedTrace Logo

A Phase 3 Trial of JKN2401 Injection in COPD

NCT07330310 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 888

Last updated 2026-01-14

No results posted yet for this study

Summary

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous JKN2401 Injection in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

BIOLOGICAL

JKN2401 Injection

JKN2401 subcutaneous injection, Q4W

OTHER

Placebo

Placebo subcutaneous injection,Q4W

Sponsors & Collaborators

  • Joincare Pharmaceutical Group Industry Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2027-09-30
Completion
2027-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07330310 on ClinicalTrials.gov